Imiglin 500mg Tablet

Introduction

Imiglin is a prescription medication that contains the active ingredient Imeglimin. It is available in tablet form and is marketed under the brand name Imiglin.

Uses

Imiglin is primarily prescribed to manage and control blood sugar levels in adults with type 2 diabetes mellitus. It is often used in combination with other antidiabetic medications, such as metformin, to enhance the effectiveness of treatment.

Dosage and Administration

The dosage of Imiglin may vary depending on individual factors such as age, weight, and the severity of diabetes. Follow the instructions provided by your healthcare professional. Typically, the recommended starting dose is one tablet taken orally with meals, twice daily. Your doctor may adjust the dosage as needed to achieve optimal blood sugar control.

Mechanism of Action

Imeglimin, the active ingredient in Imiglin, works by targeting multiple sites within the body to improve glucose utilization and reduce insulin resistance. It enhances insulin secretion from the pancreas and increases insulin sensitivity in peripheral tissues, leading to better glucose uptake and utilization by cells.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, stomach discomfort, and headache. These side effects are usually mild and temporary. If any of these side effects persist or worsen. Consult your healthcare provider.

In rare cases, Imiglin may cause serious side effects such as allergic reactions, including rash, itching, swelling, dizziness, or difficulty breathing. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications may interact with Imiglin and affect its effectiveness or increase the risk of side effects. Common drug interactions include certain antidiabetic medications, such as insulin or sulfonylureas. Your healthcare provider will carefully evaluate your medication regimen to ensure its safety and efficacy.

Precautions

Before starting treatment with Imiglin, inform your healthcare provider about any medical conditions you have, especially if you have a history of kidney or liver disease. Disclose any allergies or hypersensitivity reactions to medications.

Imiglin is not recommended for use during pregnancy or breastfeeding. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks and benefits of this medication with your healthcare provider.

Storage

Imiglin should be stored at room temperature, away from direct sunlight and moisture. Keep it out of the reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

• Take Imiglin exactly as prescribed by your healthcare provider. Do not exceed the recommended dosage or change the dosing schedule without consulting your doctor.
• maintain a healthy lifestyle while taking Imiglin, including regular exercise and a balanced diet.
• Monitor your blood sugar levels regularly as directed by your healthcare provider.
• If you have any concerns or questions about Imiglin, do not hesitate to reach out to your healthcare provider for clarification.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Chevalier C, Fouqueray P, Bolze S. Imeglimin: A Clinical Pharmacology Review. Clin Pharmacokinet. 2023 Oct;62(10):1393-1411. doi: 10.1007/s40262-023-01301-y. Epub 2023 Sep 15. [Accessed 22 Jun. 2024] Available at:
• Shrestha SC, Gupta S. Imeglimin: the New Kid on the Block. Curr Diab Rep. 2024 Jan;24(1):13-18. doi: 10.1007/s11892-023-01531-1. Epub 2023 Dec 5. [Accessed 29 Jun. 2024] Available at:
• Hallakou-Bozec S, Vial G, Kergoat M, Fouqueray P, Bolze S, Borel AL, Fontaine E, Moller DE. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. 2021 Mar;23(3):664-673. doi: 10.1111/dom.14277. Epub 2020 Dec 29. [Accessed 12 Jun. 2024] Available at:
• Giruzzi M. Imeglimin. Clin Diabetes. 2021 Oct;39(4):439-440. doi: 10.2337/cd21-0085. [Accessed 23 Jun. 2024] Available at: